Companies › TR Therapeutics
1 active drug program in 2 registered trials: 2 Phase 3; Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TR987 0.1% gel Tissue repair agent | – | Phase 3 | Venous Leg Ulcer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06707103 | TR987 0.1% gel | Phase 3 | Venous Leg Ulcer | Cardiovascular | Dec 2026 |
| NCT06707090 | TR987 0.1% gel | Phase 3 | Venous Leg Ulcer | Cardiovascular | Dec 2027 |
No annotated target.
–
Cell Biopeutics Resources Sdn Bhd Kerecis AOTI Beijing Inno Medicine Nectero Medical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.